Your browser doesn't support javascript.
loading
Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negative early breast cancer: ARTemis Trial.
Earl, H M; Hiller, L; Dunn, J A; Blenkinsop, C; Grybowicz, L; Vallier, A-L; Gounaris, I; Abraham, J E; Hughes-Davies, L; McAdam, K; Chan, S; Ahmad, R; Hickish, T; Rea, D; Caldas, C; Bartlett, J M S; Cameron, D A; Provenzano, E; Thomas, J; Hayward, R L.
Afiliação
  • Earl HM; Department of Oncology, University of Cambridge, Cambridge.
  • Hiller L; NIHR Cambridge Biomedical Research Centre, Cambridge.
  • Dunn JA; Cambridge Breast Cancer Research Unit, Cambridge University Hospitals NHS Foundation Trust, Cambridge.
  • Blenkinsop C; Warwick Clinical Trials Unit, University of Warwick, Coventry.
  • Grybowicz L; Warwick Clinical Trials Unit, University of Warwick, Coventry.
  • Vallier AL; Warwick Clinical Trials Unit, University of Warwick, Coventry.
  • Gounaris I; Cambridge Clinical Trials Unit - Cancer Theme, Cambridge University Hospitals NHS Foundation Trust, Cambridge.
  • Abraham JE; Cambridge Clinical Trials Unit - Cancer Theme, Cambridge University Hospitals NHS Foundation Trust, Cambridge.
  • Hughes-Davies L; Department of Oncology, Queen Elizabeth Hospital King's Lynn NHS Foundation Trust, King's Lynn.
  • McAdam K; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge.
  • Chan S; Department of Oncology, University of Cambridge, Cambridge.
  • Ahmad R; NIHR Cambridge Biomedical Research Centre, Cambridge.
  • Hickish T; Cambridge Breast Cancer Research Unit, Cambridge University Hospitals NHS Foundation Trust, Cambridge.
  • Rea D; Department of Oncology, University of Cambridge, Cambridge.
  • Caldas C; Department of Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge.
  • Bartlett JMS; Department of Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge.
  • Cameron DA; Department of Oncology, Peterborough and Stamford Hospitals NHS Foundation Trust, Peterborough.
  • Provenzano E; Department of Oncology, Nottingham City Hospital, Nottingham.
  • Thomas J; Department of Oncology, West Middlesex University Hospital, Isleworth.
  • Hayward RL; Department of Oncology, Poole Hospital NHS Foundation Trust/Bournemouth University, Poole.
Ann Oncol ; 28(8): 1817-1824, 2017 Aug 01.
Article em En | MEDLINE | ID: mdl-28459938
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Taxoides / Bevacizumab Tipo de estudo: Clinical_trials / Diagnostic_studies / Screening_studies Limite: Female / Humans / Middle aged Idioma: En Revista: Ann Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2017 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Taxoides / Bevacizumab Tipo de estudo: Clinical_trials / Diagnostic_studies / Screening_studies Limite: Female / Humans / Middle aged Idioma: En Revista: Ann Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2017 Tipo de documento: Article